The company explained that the U.S. Food and Drug Administration (FDA) removed its clinical hold on the studies, and will ...

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

The latest update is out from Novavax ( (NVAX)). Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza vaccine ...

Novavax (NVAX) announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its ...

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient. The U.S.

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has cut its guidance multiple times this year, and the new range is below the ...

Novavax said on Monday it had changed the participant's symptoms ... "The information provided to the FDA supported our ...

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...